ReviewChildren (Basel, Switzerland)2023
A Practical Update on Pediatric Eosinophilic Esophagitis.
Review in Children (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Assessing the psychological effects of eosinophilic esophagitis: a study on anxiety, self-concept, and depression in pediatric patients.European journal of pediatrics · 2026Article
- Gastrointestinal manifestations during oral immunotherapy: A guide for pediatric allergists.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Less Can Be Enough: Sustained Remission of Pediatric Eosinophilic Esophagitis With Low-Frequency Dupilumab.Clinical case reports · 2026Article
- Clinical Patterns and Outcomes of Eosinophilic Esophagitis in Children and Adolescents at a Tertiary Care Center in Lebanon.Children (Basel, Switzerland) · 2026Article
- Eosinophilic Esophagitis in the Middle East: Insight From a Comprehensive Systematic Review.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Dupilumab as a rescue therapy for steroid-dependent eosinophilic gastritis in a child unresponsive to elimination diet: a case report.Frontiers in pediatrics · 2026Article
- Challenges in Dietary Therapy in Pediatric Eosinophilic Esophagitis (EoE)-A Narrative Review.Nutrients · 2025Review
- Cost-utility analysis of sequential therapies for pediatric-onset eosinophilic esophagitis.Journal of pediatric gastroenterology and nutrition · 2025Article
- Traditional Chinese Medicine for Pediatric Allergic Diseases.Current allergy and asthma reports · 2025Review
- Approach to the spectrum of infant non-IgE-mediated food allergy manifestations and physiologic infant behaviors.Current problems in pediatric and adolescent health care · 2025Review
- Italian EoExpert panel recommendation for disease control, switching criteria, and follow-up in eosinophilic esophagitis from pediatric to adult age.Therapeutic advances in gastroenterology · 2025Article
- Eosinophilic esophagitis improved by the discontinuation of sublingual immunotherapy for aeroallergens: a case report.Frontiers in pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic esophagitis (EoE) is an emerging atopic disease of unknown etiology limited to the esophagus. The pathogenesis is still understood and is likely characterized by type 2 inflammation. Food allergens are the primary triggers of EoE that stimulate inflammatory cells through an impaired esophageal barrier. In children and adolescents, clinical presentation varies with age and mainly includes food refusal, recurrent vomiting, failure to thrive, abdominal/epigastric pain, dysphagia, and food impaction. Upper-gastrointestinal endoscopy is the gold standard for diagnosing and monitoring EoE. EoE therapy aims to achieve clinical, endoscopic, and histological ("deep") remission; prevent esophageal fibrosis; and improve quality of life. In pediatrics, the cornerstones of therapy are proton pump inhibitors, topical steroids (swallowed fluticasone and viscous budesonide), and food elimination diets. In recent years, much progress has been made in understanding EoE pathogenesis, characterizing the clinical and molecular heterogeneity, and identifying new therapeutic approaches. Notably, clinical, molecular, endoscopic, and histological features reflect and influence the evolution of inflammation over time and the response to currently available treatments. Therefore, different EoE phenotypes and endotypes have recently been recognized. Dupilumab recently was approved by FDA and EMA as the first biological therapy for adolescents (≥12 years) and adults with active EoE, but other biologics are still under consideration. Due to its chronic course, EoE management requires long-term therapy, a multidisciplinary approach, and regular follow-ups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.